Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 355Neoplasms 252Carcinoma, Non-Small-Cell Lung 199Colorectal Neoplasms 181Lung Neoplasms 151Prostatic Neoplasms 150Carcinoma, Hepatocellular 127Leukemia, Myeloid, Acute 96Pancreatic Neoplasms 86Multiple Myeloma 82Neoplasm Metastasis 73Recurrence 72Uterine Cervical Neoplasms 68Rectal Neoplasms 68Ovarian Neoplasms 65Stomach Neoplasms 64Triple Negative Breast Neoplasms 59Squamous Cell Carcinoma of Head and Neck 57Brain Neoplasms 56Head and Neck Neoplasms 55Glioblastoma 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Small Cell Lung Carcinoma 48Melanoma 45Endometrial Neoplasms 43Disease 43Esophageal Neoplasms 42Hematologic Neoplasms 41Glioma 41Colonic Neoplasms 41

Interventions

pembrolizumab 2lenvatinib 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Endometrial Cancer × 1 year × Clear all
NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Evergreen Therapeutics, Inc.

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡